beti-cel Zynteglo TDT
Selected indexed studies
- Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial. (Lancet, 2024) [PMID:39527960]
- Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia. (J Mark Access Health Policy, 2021) [PMID:34178295]
- Gene Therapies for Hemoglobinopathies: Efficacy, Cell Collection & Transfusion Support. (Transfus Med Rev, 2025) [PMID:41223813]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia. (2021) pubmed
- Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial. (2024) pubmed
- Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia. (2026) pubmed
- Current therapeutic landscape of β-thalassemia: focus on gene therapy. (2026) pubmed
- Gene Therapies for Hemoglobinopathies: Efficacy, Cell Collection & Transfusion Support. (2025) pubmed
- Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease. (2023) pubmed